Home Current Issue Previous Issues Published Ahead-of-Print For Authors Journal Info
Skip Navigation LinksHome > December 2012 - Volume 12 - Issue 6 > Allergen-specific immunotherapy and risk of autoimmune disea...
Current Opinion in Allergy & Clinical Immunology:
doi: 10.1097/ACI.0b013e3283588c8d
IMMUNOTHERAPY AND NEW TREATMENTS: Edited by Giovanni Passalacqua and Robert Bush

Allergen-specific immunotherapy and risk of autoimmune disease

Linneberg, Allana; Madsen, Flemmingb; Skaaby, Teaa

Collapse Box

Abstract

Purpose of review: After 100 years of experience with allergen-specific immunotherapy (SIT), an issue that is still unresolved is whether SIT can act as a trigger of, or as a risk factor for, autoimmune disease. We searched the literature for evidence on this topic.

Recent findings: Several case reports of autoimmune disease development with plausible relation to SIT have been published. Vasculitis reactions accounted for the majority of case reports retrieved in our literature search. Whether the number of reported cases is higher or lower than what would be expected by chance is not possible to determine from existing data. There are no published data on autoimmune disease development in patients participating in randomized trials of the effects of SIT. One nonrandomized pharmacoepidemiological study did not detect an increased risk of autoimmune disease development during SIT as compared with the risk during conventional allergy treatment.

Summary: In conclusion, development of autoimmune disease in allergic patients treated with SIT is rare. Nevertheless, as a principle of caution, it seems reasonable to carefully evaluate the indication for SIT, that is, risks versus benefits, in patients with established autoimmune disease or a strong family history of autoimmune disease.

© 2012 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.